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Pattern recognition receptorLipid peroxidation occurs in the context of many physiological processes but is greatly increased in various
pathological situations. A consequence of phospholipid peroxidation is the generation of oxidation-speciﬁc
epitopes, such as phosphocholine of oxidized phospholipids and malondialdehyde, which form neo-self de-
terminants on dying cells and oxidized low-density lipoproteins. In this review we discuss evidence demon-
strating that pattern recognition receptors of the innate immune system recognize oxidation-speciﬁc
epitopes as endogenous damage-associated molecular patterns, allowing the host to identify dangerous
biological waste. Oxidation-speciﬁc epitopes are important targets of both cellular and soluble pattern recog-
nition receptors, including toll-like and scavenger receptors, C-reactive protein, complement factor H, and
innate natural IgM antibodies. This recognition allows the innate immune system to mediate important
physiological house keeping functions, for example by promoting the removal of dying cells and oxidized
molecules. Once this system is malfunctional or overwhelmed the development of diseases, such as athero-
sclerosis and age-related macular degeneration is favored. Understanding the molecular components and
mechanisms involved in this process, will help the identiﬁcation of individuals with increased risk of de-
veloping chronic inﬂammation, and indicate novel points for therapeutic intervention. This article is part of
a Special Issue entitled: Oxidized phospholipids—their properties and interactions with proteins.
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Living in an aerobic environment brings along constant oxida-
tive modiﬁcation of biomolecules as part of normal tissue turn
over. Our organism is usually well equipped to provide an ade-
quate response to this physiological process and maintain homeo-
stasis. However, during certain situations such as inﬂammation,
this oxidative pressure is even more enhanced, which may cause
the accumulation of oxidized proteins and lipids [1]. To prevent
this and to ensure an appropriate response, mechanisms need to
be in place that recognize and bind such modiﬁed molecules. Sev-
eral proteins of the innate immune system have evolved to fulﬁll
this function. They respond to oxidatively damaged molecules,
thereby alarming the host while at the same time protecting it
from overwhelming or chronic inﬂammation by triggering clear-
ance mechanisms. A detailed understanding of the molecular
structures that identify “biological waste” and the proteins inter-
acting with them will provide fundamental insights into physio-
logical house keeping mechanisms of innate immunity and help
understand pathologies that may result from an impairment of
these responses.
2. Innate immunity
The innate immune system represents an evolutionary old de-
fense strategy that is present in all multicellular organisms [2].
Based on cellular and humoral responses, it provides a ﬁrst line
of defense against invading microbes. Following a pathogenic in-
sult, an inﬂammatory response is initiated, which involves the
rapid recruitment of innate immune cells, particularly neutrophils
and macrophages. These cells engulf invading microbes and start
producing a number of cytokines and chemokines that eventually
activate lymphocytes, thereby triggering adaptive immune re-
sponses. Unlike the highly speciﬁc adaptive immunity the innate
immune system typically recognizes foreign invaders by a set of
pathogen-associated molecular patterns (PAMPs), which bind to
various evolutionary conserved pattern recognition receptors
(PRRs) and act as danger signals alarming the innate immune sys-
tem. Prototypic examples for a PAMP are bacterial lipopolysaccha-
rides that bind to the prototypic PRR toll like receptor 4 (TLR-4).
Apart from cell surface receptors, PRRs can also be represented
by soluble pattern recognition proteins, like the plasma reactant
C-reactive protein, which binds phosphocholine (PC) conjugated
to (lipo)teichoic acid on capsular polysaccharides of Streptococcus
pneumoniae.
An inﬂammatory response can also be triggered by endogenous
self-structures in the absence of microbes, and such a response is gen-
erally referred to as “sterile inﬂammation” [3]. Sterile inﬂammation is
part of normal wound healing and tissue repair, which rely on an ap-
propriate inﬂammatory response to the tissue damage, as the newly
recruited leukocytes remove cellular debris and secrete proteases,
thereby allowing tissue remodeling. If the inﬂammatory insult re-
mains unresolved, this can result in chronic inﬂammation,inappropriate tissue destruction, or ﬁbrosis. In analogy to PAMPs,
sterile inﬂammation is triggered by damage-associated molecular
patterns (DAMPs), which are generated by tissue injury or break
down [4]. DAMPs can be either newly generated, damage-associated
structures like advanced glycation end products (AGEs) or host mol-
ecules that are typically sequestered inside the cells under physiolog-
ical conditions and only released as a result of cellular stress, such as
necrosis following trauma, ischemia reperfusion, or chemically in-
duced injury. Prototypic DAMPs include epitopes found on intracellu-
lar proteins like the chromatin-associated protein high-mobility
group box 1 (HMGB1) or heat shock proteins (HSPs), and have also
been shown to bind and/or activate PRRs.
3. Oxidation-speciﬁc epitopes are DAMPs
Research of the last years has shown that speciﬁc structures gen-
erated as a result of lipid peroxidation are recognized by various
arcs of innate immunity and thereby can modulate many physiologi-
cal and pathological processes [5]. The peroxidation of phospholipids
occurs during a plethora of biological processes, including cellular se-
nescence and apoptosis [6,7]. Moreover, this is greatly enhanced dur-
ing inﬂammation. As a result a number of highly reactive
phospholipid peroxidation products that can modify autologous pro-
teins and lipids are generated. For example, phosphatidylcholine,
which is present in cell membranes and low density lipoprotein
(LDL) particles, contains an sn-2 polyunsaturated fatty acid (PUFA)
that makes it particularly prone to oxidation, which results in the
generation of highly reactive breakdown products, such as malondial-
dehyde (MDA), 4-hydroxynonenal (4-HNE), and the remaining core-
aldehyde, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocho-
line (POVPC). These reactive aldehydes can generate covalent adducts
with primary amines of proteins and amino groups of lipids such
as phosphatidylethanolamine (PE), and thereby form so-called
oxidation-speciﬁc epitopes (OSEs) that are recognized by different
immune receptors in a hapten-speciﬁc manner. Because many OSEs
possess strong pro-inﬂammatory properties they have been proposed
as novel kind of DAMPs. A conceptual review on this topic has been
recently published elsewhere [5]. This review will cover primarily
OSEs that result from oxidation of PUFAs in phospholipids and novel
PRRs that have recently been identiﬁed in this context.
Lipid peroxidation occurs as a physiological process that is greatly
accelerated during certain pathologies. Indeed, oxidation products
such as oxidized phosphatidylcholine, MDA, 4-HNE and others have
been documented in virtually all inﬂammatory diseases including
atherosclerosis, pulmonary, renal, and liver diseases, as well as dis-
eases affecting the central nervous system like multiple sclerosis
and Alzheimer's disease [8–14]. Studies on the pathogenic role of ox-
idized LDL (OxLDL) have been instrumental in the identiﬁcation of a
variety of lipid peroxidation derived structures that may act as
DAMPs [5,15]. An excellent historical perspective on this has recently
been published by Steinberg and Witztum [16]. Once LDL gets
trapped in the intimal layer, it can undergo oxidation via enzymatic
as well as non-enzymatic mechanisms. The ﬁrst includes among
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The second, non-enzymatic mechanisms are mediated by free radi-
cals which can be indirectly generated by NADPH oxidases and nitric
oxide synthases. Under physiological conditions these reactions re-
quire the catalysis by transition metal ions or hemin (reviewed in
Refs. [17–21]). Both pathways can yield a variety of different adducts,
residing both on the protein as well as on the lipid moiety of LDL (for
review see Ref. [22]). To study the function of OxLDL, many models
have been established that are used as surrogates for OxLDL occurring
in vivo. One prominent example is copper-oxidized LDL (CuOx-LDL),
in which LDL is oxidized by incubation with CuSO4 for given time
points. Thus, CuOx-LDL contains many different OSEs, but is particu-
larly enriched in oxidized phospholipids. Other models such as
MDA-modiﬁed LDL and 4-HNE-modiﬁed LDL are generated by active
derivatization of LDL with MDA or 4-HNE. Thus, these models are de-
liberately enriched in the two types of aldehydic adducts, respective-
ly. The validity of these models is underscored by the fact that OxLDL
found in vivo carries OSEs, which was demonstrated by immuno-
chemical detection using speciﬁc monoclonal antibodies that recog-
nize deﬁned OSEs, such as MDA-adducts and PC of oxidized
phosphatidylcholine [8]. Subsequently, it could be demonstrated
that cells undergoing apoptosis, but not viable cells, carry the same
OSEs in their membranes, which is consistent with the fact that oxi-
dative processes are known to be triggered during apoptosis [6,7].
Therefore, OSEs do not only signify situations of increased oxidative
stress, but they are also formed under physiological conditions during
normal cellular turn over. In this, OSEs allow the host's immune sys-
tem to identify biological waste and discriminate viable from dying
cells.
A number of OSEs derived from phospholipid peroxidation have
been identiﬁed, and we will subsequently discuss the best studied
examples.
3.1. Phosphocholine (PC)
One of the best characterized OSEs is PC of oxidized phospha-
tidylcholine, whose presence has been demonstrated in athero-
sclerotic lesions and a number of other inﬂammatory settings
[8,9,12]. Upon oxidation of phosphatidylcholine, its PC head
group becomes exposed and available for recognition by immune
receptors [6,23]. Thus, the PC head group is a cryptic epitope pre-
sent in native phospholipids of LDL or viable cells that becomes
revealed and accessible for binding by pattern recognition pro-
teins as a result of conformational changes only after oxidation
or when cells undergo apoptosis. Although sphingomyelin con-
tains a PC head group as well, it is not prone to oxidative modiﬁ-
cation due to the highly saturated fatty acids it is composed of.
The PC head group has also been shown to be exposed on cell
membranes that have been damaged by complement or certain
phospholipases [24,25]. Finally, because PC is also present as com-
ponent of the capsular polysaccharide of encapsulated bacteria,
such as S. pneumoniae, as well as in other gram-positive and
gram-negative bacteria, protozoa and worms [26], it provides an
example for molecular mimicry between oxidized phospholipids
and microbial antigens.
3.2. Malondialdehyde (MDA)
MDA and its many condensation products are reliable markers
for oxidative stress and have been associated with multiple disor-
ders, including atherosclerosis, Alzheimer's disease, multiple scle-
rosis, acute lung injury, alcoholic hepatitis and diabetes [8–14].
MDA is typically generated as an oxidative degradation product
of PUFAs containing more than two methylene-interrupted double
bonds. In mammalian tissue these are represented by arachidonic
acid (20:4) and docosahexaenoic acid (DHA; 22:6). MDA can alsobe formed from prostaglandin-substrates in an enzymatic process
involving platelet thromboxane synthase [27]. In vitro, MDA
forms predominantly the low reactive enolate anion at neutral
and alkaline conditions. The reactivity increases with lower pH
when β-hydroxyacrolein becomes the predominant species. In
this state, MDA rapidly forms Michael-type 1,4-additions with nu-
cleophilic functional groups like primary amines. Of note, MDA
can form several different adducts on ε-aminogroups. For exam-
ple, MDA and monofunctional aldehydes such as acetaldehyde
have been shown to mutually enhance each other's reactivity to-
wards primary amines [28], which results in the formation of
hybrid adducts, the so-called malonacetaldehyde (MAA) adducts.
These consist of two different modiﬁcations: One adduct is a 1:1
adduct of MDA and acetaldehyde and was identiﬁed as the 2-
formyl-3-(alkylamino)butanal derivative of an amino group
(FAAB adduct). The second adduct is composed of two molecules
of MDA and one molecule of acetaldehyde and was identiﬁed as
the 4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde derivative
of an amino group (MDHDC adduct). The generation of the
MDHDC-adducts seems to require, in a ﬁrst step, the formation
of the FAAB product, and, in a second step, the generation of an
MDA-enamine. The FAAB-moiety is transferred to the nitrogen of
the MDA-enamine, forming the circular MDHDC adduct [29,30].
There is increasing evidence demonstrating that the latter adduct
is the biologically most relevant [31,32].
3.3. 4-Hydroxynonenal (4-HNE)
4-HNE, which is a product of oxidized ω−6 PUFAs, such as lino-
leic and arachidonic acids, is another lipid peroxidation break down
product that is linked to diseases such as atherosclerosis, neurode-
generative diseases, and cancer. Among the many aldehydes formed
during lipid peroxidation, α,β-unsaturated hydroxyalkenals, such as
4-HNE, are of particular interest, as they are highly reactive due to
three chemical functions: An aldehyde group on C1, a double bond
between C2 and C3 and a secondary alcohol group on C4. The carbons
C3 and C1 are electrophilic sites prone to Michael-type additions [22].
4-HNE can form stable Michael-type adducts with a hemiacetal struc-
ture on lysines, cysteines or histidines [33]. Cysteine exhibits the
highest reactivity, followed by histidine and lysine. The LDL compo-
nent apolipoprotein B, however, has been reported to be mainly mod-
iﬁed on lysine residues [34].
3.4. Carboxyethylpyrrole (CEP)
ω-(2-carboxyethyl)pyrrole (CEP)-adducts have recently gained
much attention, as they have been implicated in a series of patho-
physiological processes leading to age-related macular degeneration
(AMD). CEP is formed upon oxidation of DHA-containing lipids,
which causes the formation of reactive electrophilic phospholipid
fragments like 4-hydroxy-7-oxohept-5-enoates that convert primary
amino groups on bystander molecules into CEP derivatives [35]. The
fact that DHA is a main component of retinal photoreceptors and
highly sensitive to oxidative damage due to its six double bonds
provides an explanation for the accumulation of CEP-adducts in
retinal tissues as well as in the plasma of AMD patients.
3.5. Oxidized phosphatidylserine (OxPS)
Phosphatidylserine comprises approximately 10% of all cellular
phospholipids. In viable cells, it is preferentially found in the inner
leaﬂet. However, some cellular processes, most notably apoptosis,
cause a loss of membrane asymmetry and the exposure of phosphati-
dylserine on the outer leaﬂet of the cell membrane [36]. During apo-
ptosis, PS is one of the preferred peroxidation substrates that
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Fig. 1. Schematic representation of a dying cell bound by cellular and soluble PRRs that recognize different OSEs. Several OSEs are present in the membranes of dying cells, including
phosphocholine (PC) of oxidized phosphatidylcholine, oxidized phosphatidylserine (OxPS), oxidized cardiolipin (OxCL), malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)
adducts. Similarly, carboxyethylpyrrole (CEP) adducts are present on oxidatively damaged photoreceptors. Several PRRs of innate immunity recognize OSEs including the scavenger
receptor CD36, CRP and IgM natural antibody (NAb) EO6, which bind PC; SR-A, CFH and IgM NAb NA-17, which bind MDA-adducts; the IgM NAb LRO1 that binds OxCL, CD36 bind-
ing OxPS, and TLR2 that binds CEP-adducts. B1 cell derived natural IgM with speciﬁcity for 4-HNE have also been identiﬁed.
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oxyl species [37,38].
3.6. Oxidized cardiolipin (OxCL)
Cardiolipin contains four unsaturated fatty acid chains. It is typi-
cally found in mitochondrial membranes, but also present in LDL
[39], where it can be targeted by oxidation. OxCLs are also generated
in the process of cellular apoptosis (reviewed in Ref. [40]). For a
detailed review on the role of OxCL in apoptosis see Ref. [40].
Most of these OSEs have been shown by immunohistochemical
methods to occur in various inﬂammatory settings and during physi-
ological processes, such as cellular aging or apoptosis [6,41]. Their
recognition by receptors of innate immunity suggests an evolutionary
selection for proper differentiation of damaged molecules, cells and
cellular debris from intact molecules or viable cells. Both cellular
and humoral components of innate immunity mediate this function(Fig. 1). It is likely that many more OSEs exist, including non-
phospholipid derived structures [5].
4. Cellular PRRs recognize OSEs
4.1. Scavenger receptors (SRs)
The notion that OSEs are recognized by receptors of innate immuni-
ty stems from the initial search for a scavenger receptor for OxLDL. A
number of SRs have been identiﬁed, including CD36, SRA-1 and A-2,
SR-BI, MARCO, LOX-1, and others (for review see Ref. [42]). Although
they all have been found to bind OxLDL, they recognize a variety of dif-
ferent patterns including structures identical to microbial PAMPs
[42,43]. CD36 has been identiﬁed as a major SR for OxLDL [16,44] and
it is now clear that it accounts for most of the binding and uptake of
OxLDL by macrophages [45]. Binding of OxLDL to CD36 has been
shown to be mediated by oxidized phospholipids, such as POVPC.
In fact, this binding is in part mediated by the PC head group of
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ate recognition [46]. Both, PC-epitopes of oxidized phosphatidylcho-
line conjugated to proteins such as bovine serum albumin (BSA)
or lipids mediate binding and uptake by the class B scavenger
receptors, CD36 and SR-B1. This mode of interaction is also
supported by studies, in which the PC-speciﬁc monoclonal natural
IgM EO6 (see below) inhibited the binding of POVPC-modiﬁed BSA
to CD36 and SR-B1 [6,46,47]. Importantly, both POVPC-BSA and
EO6 were shown to completely inhibit the uptake of apoptotic cells
by macrophages in vitro [6]. These data identify PC on OxLDL as
well as apoptotic cells as critical DAMP for recognition by
macrophage scavenger receptors. Interestingly, PC seems to be
recognized by CD36 only as part of oxidized phosphatidylcholine
present in OxLDL or on apoptotic cells, indicating the importance of
the context in which the epitope is presented [46]. Additionally, ox-
idized PC-containing phospholipids have been shown to activate
platelets via CD36 thereby promoting a prothrombotic phenotype
[48]. The interaction of oxidized phospholipids with CD36 has also
been suggested to be mediated by oxidized moieties on the sn-2
side chain of oxidized phospholipids, irrespective of the head group
[49,50]. These aspects of oxidized phospholipid recognition are
reviewed in Ref. [51].
Consistent with the identity of CD36 as PRR, multiple other ligands
for it have been described [52]. Early studies identiﬁed an interaction
between CD36 and phosphatidylserine [53,54]. In these experiments,
however, no measures were taken to prevent oxidation and it
has eventually become evident, that CD36 binds OxPS, rather than
phosphatidylserine, on the surface of apoptotic cells [55]. The uptake
of apoptotic cells could be competed in vitro by addition of excess
amount of OxPS, but not native PS, indicating OxPS as another ligand
for CD36 on the surface of apoptotic cells [55].
In analogy to the interaction of the OSEs PC and OxPS with CD36,
other SRs may also bind speciﬁc OSEs. For example, SR-B1 and SR-A
have also been shown to bind OxLDL [56] and the latter may serve
as a receptor for MDA epitopes [57].4.2. Toll-like receptors (TLRs)
TLRs represent classic PRRs of innate immunity, as they typically
sense microbial PAMPs and initiate a host response to ﬁght an infection.
In the last years, however it became apparent that certain TLRs can
also be activated by endogenous ligands such as heat shock proteins,
hyaluronan, and heparan sulphate (reviewed in Ref. [3]). Oxidized
1-palmitoyl-2-arachidonyl-sn-glyero-3-phosphocholine (OxPAPC),
which contains many different oxidized phospholipid species, has
been shown to alter TLR4 complex formation with CD14 on endothe-
lial cells [58,59]. This has been found to involve binding of oxidized
phospholipids to CD14 and an altering of caveolar membranes [58].
For a detailed review on these aspects see Refs. [60,61]. Importantly,
the binding to CD14 in its soluble form and to other lipoprotein-
binding proteins seems to be responsible for the ability of OxPAPC
to dampen LPS-induced TLR4 activation [59]. On the other hand,
OxPAPC was shown to induce an inﬂammatory response in alveolar
macrophages via TLR4 [9]. Although the exact epitope in OxPAPC
responsible for this has not been identiﬁed, there is evidence
supporting a role for PC, as the PC-speciﬁc IgM EO6 blocked IL-6
secretion induced by oxidized lung surfactant in macrophages [9].
Furthermore, the binding of OxLDL to CD36 has been shown to trig-
ger an inﬂammatory response through the assembly of a TLR4/TLR6
heterodimer [62]. Only future studies using speciﬁc oxidized phos-
pholipids and other lipids of OxLDL will help deﬁne the exact
interactions.
Another evidence for the involvement of TLRs in recognizing OSEs
has been recently demonstrated by West et al. In their elegant study
they could show that CEP-modiﬁcations are bound by TLR2 in vitro,and that TLR2, but not TLR4 are required for a CEP-induced angiogen-
ic response in endothelial cells in vivo [63].
Thus SR and TLR are PRRs that recognize OSEs. Despite their promis-
cuity for several ligands any given receptor or combination of receptors
seems to have speciﬁcity for one certain epitope. This speciﬁcity as well
as the cooperation of a given repertoire of receptors on the surface of a
cell transmits signals that link oxidative stress with innate immunity.
5. Soluble PRRs recognize OSEs
Similar to cellular PRRs, there are also soluble pattern recognition
proteins that can bind molecular patterns. Some of these soluble PRRs
are the secreted forms of cell surface PRRs, and may either act as
decoy receptors or as vehicles to deliver the ligand to signaling recep-
tors. Other soluble PRRs include members of the pentraxin family,
such as C-reactive protein (CRP) or complement proteins, as well as
germ line encoded natural antibodies, with various effector functions
that will be discussed below.
5.1. C-reactive protein
CRP is a highly conserved pentameric pattern recognition mole-
cule that is mainly produced by hepatocytes [64]. The plasma concen-
tration of CRP rises rapidly in response to inﬂammation, making it a
prototypical acute phase reactant and suggesting that it contributes
to host defense. Due to its upregulation in bacterial infections, it is
commonly used as a diagnostic marker for clinical purposes. Because
CRP is moderately elevated even in chronic inﬂammatory states, it
has also become a valuable biomarker for inﬂammation and cardio-
vascular disease [65].
CRP was originally identiﬁed because of its ability to bind PC cova-
lently attached to the capsular polysaccharide of S. pneumoniae. The
recruitment of CRP to the surface of pneumococci and other patho-
gens that carry PC is calcium dependent and can promote their clear-
ance [66–69]. However, CRP also binds to the PC moiety of oxidized
phosphatidylcholine present in OxLDL and apoptotic cells, where
CRP triggers the early steps of the classical complement pathway,
while limiting the amount of membrane attack complex [70,71].
Thereby, CRP binding improves opsonization and phagocytosis of ap-
optotic cells by macrophages, and promotes their silent clearance
[71]. The impact of CRP on the uptake of OxLDL was tested by exoge-
nously adding a mix of OxLDL and CRP to macrophages in vitro. These
studies suggest that CRP facilitates the uptake of OxLDL [72,73],
though the in vivo relevance of this is still unknown.
5.2. Complement factor H
CFH is a 155 kDa glycoprotein that is made up of 20 complement
control protein (CCP) modules and is the major inhibitor of the alter-
native pathway of complement activation [74]. It binds to C3b, there-
by accelerating the decay of the alternative pathway C3-convertase
while at the same time acting as a cofactor for the factor I-mediated
proteolytic inactivation of C3b to iC3b. CFH regulates complement
both in ﬂuid phase and on cellular surfaces. However, while CFH
binds and inactivates promptly C3b in ﬂuid phase, the inactivation
of surface-bound C3b by CFH is dependent on the chemical composi-
tion of the surface to which C3b is bound. The afﬁnity of CFH for C3b is
strongly increased in the presence of sialic acid and other polyanionic
molecules typically present on host cells [74].
We recently discovered that MDA epitopes are bound by CFH. This
binding seems to require the presence of advanced MAA-adducts such
as MDHDC and is Ca2+ and Mg2+ independent. It is mediated via CCP
7 and 20 within the CFH molecule, which could cooperatively mediate
the interaction of CFH with MDA. We could further demonstrate that
the common CFH SNP rs1061170, which leads to a Y>H exchange in
amino acid 402 of CCP 7, results in decreased binding to MDA. MDA
CFH
C3b iC3b
iC3b opsonization
MDA
CFHR1/3
CFH
C3b
no iC3b opsonization
MDA
Fig. 2. Model of competition between CFH and CFHR1/3 on MDA-decorated surfaces. (A) CFH binds to MDA on the surface of apoptotic cells, where it promotes factor I-mediated
cleavage of C3b into iC3b. (B) CFHR1 and 3 lack a complement regulatory function but contain potential MDA-binding motifs and may therefore compete with CFH for MDA binding,
leading to reduced anti-inﬂammatory iC3b generation on MDA-decorated surfaces.
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and necrotic cells as well as apoptotic blebs. CFH exerts its cofactor ac-
tivity on MDA-decorated surfaces, leading to the local generation of
the anti-inﬂammatory iC3b fragment. Furthermore, CFH directly neu-
tralizesMDA-induced IL-8 production bymacrophages aswell as retinal
pigment epithelium cells [75]. In analogy to this, CFH has been previ-
ously shown to inhibit TNFα production by endothelial cells that were
stimulated with apoptotic blebs [76]. We therefore speculate that this
pro-inﬂammatory response is mediated by MDA epitopes on the
surface of apoptotic blebs.
CFH is one representative of a family of complement regulators,
whose other members, the so-called CFH-related proteins do not
have a complement regulatory function, but share high sequence ho-
mology with the MDA-binding domains of CFH [74]. Competition as-
says suggested that CFHRs may interfere with the complement
regulatory activity of CFH on MDA-decorated surfaces [75]. This is of
particular interest, as this observation may provide an explanation
for the fact that deﬁciencies in CFHR1 and CFHR3 were found to pro-
tect from age-related macular degeneration. Both CFHRs could com-
pete with CFH for the binding to MDA epitopes in vivo, thereby
preventing CFH to mediate its complement regulatory activity at
these sites (Fig. 2) [77].
5.3. Natural antibodies
NAbs represent another humoral component of innate immunity.
The main source of NAbs, which are predominantly of the IgM class,
is a speciﬁc B-cell subtype called B-1 cells [78,79]. The latter can be
distinguished from the conventional B-2 cells by their surface marker
expression, anatomical localization and activation requirements. Be-
cause their antigen binding sites are typically generated by the re-
combination of germ line encoded variable genes, these Abs have
only a limited repertoire of binding speciﬁcities for diverse structures,
such as (phospho)lipids and carbohydrates [80]. NAbs have speciﬁci-
ty for both microbial and self antigens, which enables them to act in
the ﬁrst line defense against infections but also to provide house
keeping functions by promoting the clearance of cellular debris. It is
believed that both functions have led to a positive selection of certain
speciﬁcities during evolution [80]. Recently, we found that OSEs are
major targets of IgM NAbs in mice and humans [81]. The prototypic
example of a NAb with speciﬁcity for OSEs is T15/EO6, which has
speciﬁcity for PC. EO6 was originally cloned as an anti-OxLDL mAb
from the spleens of atherosclerotic ApoE−/− mice, which have very
high titers of IgM Abs against epitopes of OxLDL [8]. Subsequent char-
acterization of its variable regions of both heavy and light chain
revealed a 100% sequence identity with the prototypic anti-PC NAbT15 [82]. T15 has been studied for over 30 years for its ability to con-
fer optimal protection from lethal infections with S. pneumoniae by
binding the PC of capsular polysaccharide (CPS) [83]. Thus, T15/EO6
Abs recognize PC as part of oxidized phosphatidylcholine as well as
PC directly conjugated to (lipo)teichoic acid of CPS. This dual speciﬁc-
ity allows it to act in the ﬁrst line defense against microbial infections
as well as in mediating homeostatic house keeping functions.
Besides PC, IgM NAbs against other OSEs have also been described.
For example, another anti-OxLDL monoclonal IgM Ab, LRO1, that was
cloned from the spleens of hypercholesterolemic LDLR–/– mice was
found to have speciﬁcity for oxidized, but not native cardiolipin. The
variable region of this mAb is also encoded by germ line genes, and
also binds to the surface of apoptotic but not viable cells [84].
To study the repertoire of NAbs with speciﬁcity for OSEs, we have
selectively reconstituted immunodeﬁcient recombinase activating
gene (RAG)-1−/−mice with B-1 cells. Thus, by deﬁnition all immuno-
globulins found in plasma of these mice are B-1 cell derived NAbs.
Plasma of these mice contained primarily immunoglobulins of the
IgM class and of all IgM NAbs that showed speciﬁcity to OSEs, includ-
ing CuOx-LDL, MDA-LDL, and 4-HNE-LDL. IgM against MDA-adducts
were the most prevalent. In fact, ~15% of all IgM NAbs were found
to bind to MDA-type adducts, suggesting a great need to defend
against this speciﬁc modiﬁcation [81]. Indeed, MDA and MDA-
modiﬁed proteins are known to induce inﬂammatory responses and
are recognized by innate immunity [31,57]. We also cloned an IgM
NAb with speciﬁcity for MDA-LDL from the spleens of B-1 cell recon-
stituted mice. This clone, termed NA-17, displayed complete germ
line usage except for one nucleotide insertion in the variable region
of the light chain. Importantly, consistent with the presence of MDA
epitopes on the surface of dying cells, NA-17 strongly stained apopto-
tic cells and accelerated their in vivo clearance by macrophages [81].
The notion that OSEs are dominant targets of NAbs is also supported
by studies using umbilical cord plasma as source of human NAbs. Un-
like IgG, IgM Abs do not pass the placental barrier and therefore are
exclusively of fetal origin, representing the human equivalent for
NAbs. Consistent with the data obtained in mice, human umbilical
cord blood contained high titers of IgM Abs against MDA-LDL and
CuOx-LDL, but not against native LDL or an irrelevant protein [81].
Thus, OSEs represent major DAMPs for both cellular and soluble
PRRs that recognize speciﬁc epitopes in a hapten-speciﬁc manner. Be-
cause the generation of OSEs is associated with cellular death or oxi-
dative damage of molecules, these epitopes represent critical tags
that allow innate immunity to distinguish between viable and dam-
aged or dying cells on the other hand. For example PC of oxidized
phosphatidylcholine present in OxLDL and membranes of dying
Table 1
Innate immune receptors interacting with OSEs and major functional consequences thereof.
OSE Humoral PRRs Cellular PRRs
PC CRP: Ca2+-dependent interaction; facilitates clearance
of apoptotic cells and OxLDL in vitro [70,71]
EO6/T15 IgM: blocks binding of OxLDL to CD36 [46]
and SR-B1 [47] in vitro [6]; inhibits proinﬂammatory
effects of oxidized phospholipids and apoptotic cells [9,109];
promotes clearance of apoptotic cells in vivo [107]; protects
from atherosclerosis [110,111]
CD36: major SR responsible for OxLDL uptake [44]; binding to
OxLDL triggers assembly of TLR4/6 heterodimer [62]; mediates
uptake of oxidatively damaged photoreceptors [116]
SR-B1: mediates OxLDL uptake, which can be competed by
EO6/T15 [48]
MDA CFH: binds via CCP 7 and 20, neutralizes proinﬂammatory
properties of MDA, mediates iC3b generation, implications for
age-related macular degeneration [75]
NA-17 IgM: promotes clearance of apoptotic cells in vivo [81]
SR-A: may serve as a receptor for MDA-LDL [57]
4-HNE IgM NAbs [81] ?
OxCL LRO1 IgM [84] ?
CEP ? TLR2: mediates CEP-induced angiogenic response [63]
OxPS MFG-E8: mediates clearance of apoptotic cells by macrophages [85] CD36: important for the uptake of apoptotic cells via oxidized
phosphatidylserine
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analogy, MDA-adducts, also present in membranes of dying cells, are
recognized by SR-A, CFH, and NAbs such as NA-17. Similarly, other
OSEs such as OxCL or 4-HNE adducts are recognized by IgM NAbs,
and we hypothesize that they too are also bound by a set of other
PRRs. In addition, OxPS has been suggested to be bound by milk fat
globule epidermal growth factor 8 (MFG-E8), which promotes the
clearance of apoptotic cells by macrophages [85]. The interaction of
OSEs with cellular and humoral PRRs is summarized in Table 1. The
fact that such a high variety of PRRs is directed at speciﬁc OSEs under-
lines the need and importance to respond to them. Each of these PRRs
fulﬁlls an important physiological and non-redundant role in tissue ho-
meostasis, which becomes even more critical under situations of in-
creased oxidative stress. In analogy to PC of oxidized
phosphatidylcholine and pneumococci, it is hypothesized that for many
if not all OSEs identical or equivalent structures on microbial antigens
exist.
6. Disease implications
The described innate responses to OSEs have critical physiological
house keeping functions as they protect from the negative conse-
quences of the accumulation of cellular debris and oxidized mem-
branes. If this process is intrinsically impaired or once it becomes
overwhelmed, critical house keeping functions cannot be maintained
which may trigger various pathologies. Chronic inﬂammatory pro-
cesses in particular can be the consequence of either inefﬁcient
responses to oxidative stress and/or the accumulation of oxidation
products beyond the immune system's capacity.
6.1. Atherosclerosis
Atherosclerosis is a chronic inﬂammatory disease of the vascular
wall and the underlying cause for heart attacks and a majority of
strokes. It is a prototypic disease of increased oxidative stress with a
complex pathogenesis that is inﬂuenced by many variables. One of the
main factors contributing to the development of atherosclerotic lesions
is an increased level of LDL cholesterol. The oxidation of LDL in the inti-
mal space is one of the initiating events in the development of athero-
sclerotic lesions. Oxidative neoepitopes present on OxLDL facilitate
SR-mediated uptake of OxLDL by macrophages. Once the levels of inti-
mal OxLDL get too high,macrophages start to accumulate OxLDL result-
ing in foam cell formation. This is a key event in atherosclerotic lesion
formation. In vitro experiments have demonstrated that up to 90% of
OxLDL is taken up by macrophages via CD36 and SR-A [45]. Comparing
human CD36 deﬁcientmonocyte/macrophageswith normalmonocyte/
macrophages conﬁrmed that about 50% of the OxLDL uptake can beattributed to CD36 [86]. Because this uptake also enhances the clear-
ance of pro-inﬂammatory OxLDL in the presence of a functional
cholesterol efﬂux activity, it may well be regarded initially as a
protective response. In this way SRs fulﬁll a homeostatic function, and
may therefore be also beneﬁcial during early stages of atherosclerotic
lesion formation. However, once OxLDL levels exacerbate in the
atherosclerotic intima, SRs contribute to foam cell formation and
thereby lesion progression. On the one hand they do so by binding of
OSE-modiﬁed proteins, which triggers inﬂammatory responses
[62,75]. On the other hand, owing to the cholesterol overload, foam
cells eventually undergo apoptosis resulting in the accumulation of ap-
optotic cells that compete for the uptake bymacrophages. If not swiftly
cleared they further contribute to the pool of pro-inﬂammatory OSEs
within atherosclerotic lesions [87]. In line with the quality of this
response, atherosclerosis studies performed using SR-deﬁcient mice
have yielded different results depending on the anatomical site, stage
of atherosclerosis and sex of the animal [88–90].
A similar house keeping function could be carried out by humoral
PRRs that recognize OSEs. For example, CRP has been reported to pro-
mote the clearance of apoptotic cells in vitro [71]. Elevated levels of
the CRP are a robust and independent biomarker for inﬂammation
and the development of CVD. Although it is intriguing to speculate
that the ability of CRP to bind PC of oxidized phosphatidylcholine
could mediate a protective effect in atherosclerosis, there is little ev-
idence supporting such a role. In fact initially many in vitro data sug-
gested a pro-inﬂammatory function of CRP on vascular cells [65]. A
number of studies have been conducted to assess the role of human
CRP (mice do not express CRP) in various mouse models of athero-
sclerosis. Both passively administered human CRP and transgenically
expressed CRP showed no conclusive effect on atherosclerosis devel-
opment in mice [91–96].
In analogy to CRP, which binds PC of oxidized phosphatidylcho-
line, we have recently identiﬁed CFH as major MDA-binding protein
in plasma. We and others have demonstrated the presence of CFH
in atherosclerotic lesions [75,97,98] and CFH has been suggested to
inhibit complement activation during atherogenesis [99]. Intriguing-
ly, efﬁcient clearance of CRP-labeled apoptotic cells requires the pres-
ence of CFH [71]. Therefore, by carrying CRP-binding PC- as well as
CFH-binding MDA epitopes on their surface, apoptotic cells provide
the ideal platform for complement mediated opsonization and clear-
ance. Recently, a number of studies have evaluated the association of
the CFH Y402H polymorphism, which impairs MDA binding, with the
risk of coronary heart disease (CHD), ischemic stroke, and venous
thromboembolism [99–101]. In a prospective cohort, the CFH
Y402H polymorphism was associated with an increased risk for myo-
cardial infarction. However, these results have not been consistent in
multiple smaller cross-sectional or case-control studies, and no study
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hort, the CFH 402H allele was associated with an increased risk for in-
cident CHD and ischemic stroke in whites, with the strength and
signiﬁcance of the association depending on the presence of hyper-
tension [103]. A comprehensive meta-analysis published in 2010
based on eight different patient cohorts, however, did not ﬁnd any
association of the CFH Y402H variant with CHD [104].
There is now accumulating evidence demonstrating that plasma
levels of IgM antibodies directed against models of OxLDL, such as
MDA-LDL and CuOx-LDL are inversely correlated with the risk for cor-
onary artery disease or carotid atherosclerosis. In fact, LDLR–/– mice
deﬁcient in secreted IgM develop accelerated atherosclerosis [105].
Moreover, transfer of B-1 cells into splenectomized ApoE–/– mice
conferred atheroprotection, but this effect was lost when B-1 cells
from sIgM–/– ko mice were transferred [106]. Because, a large part
of natural IgM has speciﬁcity for OSEs it can be hypothesized that
IgM NAb with these speciﬁcities mediate atheroprotection in part
by promoting the clearance of cellular debris and neutralizing inﬂam-
matory activities of OSEs. IgM antibodies are important for comple-
ment mediated clearance of apoptotic cells [107]. This has been
shown for the PC-speciﬁc IgM EO6, which both accelerates the clear-
ance of apoptotic cells in vivo and neutralizes the pro-inﬂammatory
effects of apoptotic blebs and oxidized phospholipids on endothelial
cells and macrophages, respectively [9,108]. Furthermore, EO6 has
been shown to inhibit the upregulation of IL-8 in endothelial cells
after stimulation with apoptotic cells [109]. Similarly, the MDA-
speciﬁc IgM NAb NA-17 has been shown to signiﬁcantly enhance the
uptake of apoptotic cells by macrophages in vivo [81]. We propose
that NAbs inhibit SR-mediated uptake while at the same time promot-
ing the clearance of OxLDL and apoptotic cells by other mechanisms
involving complement.
Important insights for a role of OSE-speciﬁc IgM in atherogenesis
came from experiments that exploited the molecular mimicry
between pneumococci and OxLDL. We could show that immunizing
mice with pneumococcal extracts resulted in robust production of
anti-OxLDL IgM Abs. This increase in PC-speciﬁc IgM titers was nearly
exclusively due to the expansion of EO6/T15id+IgM, and cholesterol-
fed LDLR–/– mice immunized with this protocol resulted in
signiﬁcantly decreased lesion formation [110]. Faria-Neto et al. subse-
quently corroborated the atheroprotective role of this IgM clone in
demonstrating that passive transfer of T15id+IgM reduced atheroscle-
rosis in a vein graft atherosclerosis model [111]. Because IgM titers
against other OSEs, most prominently MDA, are manifold higher
than PC-speciﬁc titers, MDA-speciﬁc IgM NAb may provide even
greater production. We speculate that the combined response of mul-
tiple OSE-speciﬁc IgM NAb has the capacity to provide optimal pro-
tection from atherosclerotic lesion formation.
6.2. Age-related macular degeneration (AMD)
AMD is the leading cause of irreversible blindness in older adults
in industrialized countries [112,113]. The pathogenesis of AMD, a de-
generative disorder affecting the retina that leads to irreversible vi-
sion loss, has been linked to increased oxidative stress [114,115].
Intense light exposure has been shown to generate oxidized phos-
pholipids on the surface of outer photoreceptor segments, which
leads to their uptake by retinal pigment epithelium cells in a CD36-
dependent manner [116]. A hallmark of developing AMD is the accu-
mulation of extracellular deposits, termed drusen, which have been
shown to contain 4-HNE-, MDA-, as well as CEP-modiﬁed proteins
[117]. Mice that were sensitized by immunization with CEP-
adducted proteins display complement deposition in the eyes and de-
velop signs of AMD [114]. On top of this, CEP-adducts have been
shown to directly promote angiogenesis in a VEGF-dependent man-
ner during laser-induced choroidal neovascularization, a model for
the neovascular form of AMD [118]. In ischemia reperfusion andwound healing models, CEP induced VEGF secretion via a MyD88-
dependent TLR2 signaling [63].
Several risk factors increase the susceptibility to AMD. Apart from
advanced age, these include environmental factors like smoking as
well as genetic factors [113]. In 2005, several independent research
groups reported that the single nucleotide polymorphism
rs1061170 in the CFH gene substantially increases the risk for devel-
oping AMD [119–122]. This variant has a frequency of 35% and may
be responsible for more than 50% of all AMD cases [123,124]. Because
we demonstrated that the amino acid substitution caused by this
polymorphism substantially impairs the ability of CFH to bind to
MDA epitopes, our ﬁndings provide a direct connection between ox-
idative stress and AMD pathogenesis. Furthermore, the risk variant
of CFH has strongly impaired cofactor activity on MDA-decorated sur-
faces, such as represented by apoptotic cell membranes, and this may
result in increased inﬂammatory responses due to inefﬁcient clear-
ance of cellular debris. Indeed, we showed that intravitreal injections
of MDA-modiﬁed BSA in mice trigger IL-8 production in the retinal
pigment epithelium, which was neutralized by simultaneous injec-
tion of CFH. The disease-associated variant of CFH may have reduced
efﬁciency in neutralizing the pro-inﬂammatory effects of MDA. Future
studies will show whether other SNPs predisposing for AMD also
result in impaired MDA-binding capacity.
7. Conclusions
In this article we reviewed the existing evidence that identiﬁes
OSEs as important targets of innate immunity. Because of their capac-
ity to induce inﬂammatory responses, OSEs represent endogenous
danger signals that qualify as DAMPs. A variety of cell-associated as
well as soluble PRRs have been found to target speciﬁc OSEs and pro-
vide critical house keeping functions of innate immunity. These in-
clude TLRs, SRs, as well as plasma proteins of innate immunity, such
as CRP and CFH, and NAbs. All of these recognize OSEs as structural
motifs that are generated as a consequence of lipid peroxidation.
OSEs are generated in virtually all inﬂammatory processes and there-
fore ubiquitously present in various pathologies. The most abundant
and relevant source of OSEs are lipoproteins as well as apoptotic
cells, blebs, and cellular debris. Because programmed cell death oc-
curs throughout life, it is clear that the need to respond to and remove
dying cells efﬁciently represents a profound evolutionary pressure for
the innate immune system. In this regard, OSEs are an intriguing tar-
get for PRRs, as they are only present in dying cells but not viable
cells. Thereby, both cell-associated and soluble PRRs have the ability
to distinguish between—potentially dangerous—dying cells, and via-
ble healthy cells on the other hand. The fact that the same innate re-
sponses also target equivalent microbial PAMPs may provide an
additional selection pressure.
The recognition of OSEs by innate immune receptors is highly rel-
evant to various diseases, including atherosclerosis and AMD. The
swift removal of dying cells is particularly imperative in these dis-
eases, and several layers of immunity need to ensure this vital pro-
cess. Once this system fails or becomes overwhelmed, cellular
debris starts to accumulate resulting in inﬂammation, adverse im-
mune activation, and disease. This can be a consequence of genetical-
ly impaired functions of the players involved or a chronically
increased generation of oxidized waste. The latter is the case for dis-
eases of increased oxidative stress. OxLDL in atherosclerotic lesions,
as well as oxidatively damaged photoreceptors in the retina contain
OSEs and therefore compete for the same clearance mechanisms as
dying cells. Thus, in these sites of increased oxidative stress the
threshold at which these homeostatic house keeping functions of in-
nate immunity fail is much lower compared to other tissues, which
increases their vulnerability. A better understanding of the identity
and function of the molecular players involved will ultimately help
identify individuals that possess a higher risk for disease. Moreover,
2473D. Weismann, C.J. Binder / Biochimica et Biophysica Acta 1818 (2012) 2465–2475this may also lead to novel therapeutic strategies that exploit endog-
enous protective mechanisms.
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